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Abstract 
 
Whether tumorigenic cancer stem cells (CSCs) exist in melanoma has been the 
focus of much controversy in recent years. A number of studies have pointed to 
the existence of melanoma cell sub-populations that act as CSCs and can be 
distinguished from other tumor cells based on specific surface marker 
expression or specific properties such as the capacity for extensive self-renewal. 
Other studies failed to identify melanoma stem cells and proposed that the 
potential to initiate tumors is a wide spread feature in melanoma inherent to 
most if not all cells of the tumor mass. As with normal stem cells, the term CSC is 
based on an operational definition, indicating not just a tumor-initiating cell, but 
also a cell with the capacity to sustain long-term tumor propagation. Therefore, 
the experimental set-up chosen to identify putative CSCs in melanoma is crucial: 
Both the method of tumor cell preparation and the procedure used to assess CSC 
properties in vivo influence the experimental outcome and hence its 
interpretation. In this review, we summarize our current knowledge on CSCs and 
the role of stem cell properties in melanoma and discuss recent findings with 
respect to their clinical relevance.  
 
 
1. Introduction 
 
Metastatic melanoma represents the most aggressive skin cancer, characterized 
by extremely poor survival. Despite decades of advances in melanoma research 
and drug development, the battle against this disease is still ongoing. The CSC 
model postulates that only a fraction of cells within a tumor has the capacity to 
initiate and sustain tumor growth. If correct, this model would provide a basis 
for more successful and advanced melanoma therapies that target specifically 
tumorigenic CSCs. It is believed that CSCs (sometimes also referred to as “tumor-
initiating cells” or “cancer-initiating cells”) share common features with 
corresponding tissue stem cells, namely their ability to self-renew and to give 
rise to hierarchically organized tissues composed of a variety of cell types. The 
CSC concept has recently been verified in vivo by three independent studies 
using cell fate mapping techniques in mouse models of skin, intestine and brain 
tumors. These studies demonstrated for the first time the existence of CSCs in 
vivo [1], [2] and [3].  
 
Of note, however, the term CSC does not indicate that CSCs originate from the 
genetic deregulation of normal stem cells. As in many other cancers, the cell of 
origin of melanoma remains unknown, and it cannot be excluded that melanoma 
arise from the accumulation of genetic mutations in melanocytes acquiring stem 
cells features via somatic reprogramming. In addition, melanoma might derive 
from normal stem cells present in the skin, such as melanocyte stem cells or 
other adult stem cells. During development, melanocytes originate from a 
transient embryonic structure called the neural crest. This structure comprises 
cells dubbed embryonic neural crest stem cells (eNCSCs), which upon isolation 
can self-renew and generate a variety of neural and non-neural cells types, 
including melanocytes [4]. Intriguingly, cells with a very similar potential as 
eNCSCs have been isolated from various adult organs containing neural crest 
derivatives, including skin [5] and [4]. In mice, genetic in vivo fate mapping 
showed that these cells indeed originate during embryonic development from 
the neural crest. Based on their potential and origin, these cells were therefore 
termed neural crest-derived stem cells or also adult NCSCs. Cell lineage tracing 
experiments further demonstrated that murine adult NCSCs are associated with 
the glial and melanocytic lineages in the trunk skin, while in the face they were 
also found in mesenchymal structures such as the dermal papilla [6], [7] and [8]. 
More recently, Herlyn and colleagues described a population of dermal stem cells 
present in the human skin and exhibiting NCSC properties [9]. Similar to adult 
NCSCs, these dermal stem cells express the low-affinity neurotrophin receptor 
p75 (p75NTR, CD271), a marker of NCSCs, and are capable to self-renew and 
differentiate into mesenchymal, neuronal, and melanocytic lineages. Although 
genetic lineage tracing is obviously not possible in human, the similarities 
between murine adult NCSCs and human CD271-positive dermal stem cells 
suggest that these cells might indeed represent the same or overlapping cell 
populations, although further studies are needed to address this issue.  
 
While our knowledge on eNCSCs is quite advanced, little is known about the 
biology of adult cells with NCSC properties. In particular, the physiological role of 
adult NCSCs in vivo remains to be discovered. Conceivably, however, adult NCSCs 
might also play a pathophysiological role, revealing their potential upon 
oncogenic transformation and thereby giving rise to melanoma and other tumors 
of neural crest origin. The idea that melanoma might derive from a cell with 
NCSC characteristics is consistent with histopathological findings and gene 
expression signatures associated with melanoma development [10]. 
Histologically, melanoma is a very heterogeneous tumor and, in addition to 
melanocytes, is often composed of cells with neuronal, glial, chondrocytic, and 
adipocytic features [11], [12], [13], [14], [15] and [16]. Therefore, it is plausible 
that melanoma-initiating cells display NCSC characteristics, sharing similar 
surface marker phenotypes and regulatory signalling pathways. Here, we 
summarize our knowledge on melanoma stem cells, markers used to identify 
these cells, and experimental strategies to isolate these cells and to test their 
tumorigenic potential.  
 
 
2. Cell surface markers for the prospective identification of putative CSCs in 
melanoma 
 
In 2005, Meenhard Herlyn and colleagues provided the first evidence for CSCs in 
human melanoma, reporting that metastatic melanoma lesions from human 
patients contained a cell population with stem cell-like properties [17]. In 
analogy to other groups, they have used in vitro sphere culture conditions to 
enrich for cells with stem cell features. Surprisingly, cells within spheres 
expressed the B cell marker CD20 (also known as MS4A1) [17]. The melanoma-
derived spheres demonstrated not only a differentiation potential reminiscent of 
neural crest cells in vitro giving rise to melanocytes, adipocytes, osteocytes and 
chondrocytes, but also the ability to self-renew in vitro and in vivo (Table 1).  
 
ABCB5 (ATP-binding cassette subfamily B member 5) belongs to the superfamily 
of active transmembrane transporters that act as ATP-dependent pumps to 
transport a variety of compounds out of the cell. ABCB5 was detected in a 
subpopulation of primary melanocytes (11%), cultured melanoma cells (3%), 
human melanoma tissue, and its expression correlates with melanoma 
progression [18], [19] and [20]. Furthermore, ABCB5 expression within human 
melanoma was observed in non-pigmented, undifferentiated cells. The ABCB5-
positive population was able to sustain tumor growth when xenotransplanted 
into NOD/SCID mice, to serially self-renew in vivo giving rise to secondary 
tumors, and to re-establish the cellular heterogeneity characteristic of melanoma 
(Table 1). Strikingly, selective elimination of the ABCB5 population using a 
monoclonal antibody against ABCB5 in NUDE mice inhibited melanoma growth 
[20]. Recently, Frank and colleagues reported the identification of circulating 
tumor cells (CTCs) in peripheral blood mononuclear cell fractions of melanoma 
patients characterized by expression of ABCB5 [21]. When prospectively isolated 
and xenotransplanted into NOD/SCID/Il2-/- mice, ABCB5-positive CTCs 
generated metastases demonstrating that CTCs have tumorigenic potential and 
the ability to become invasive [21]. Interestingly, the frequency of melanoma 
CTCs found in the bloodstream of patients correlated with tumor progression 
and patient survival. ABCB5 expression on melanoma circulating cells might 
therefore serve as a biomarker for melanoma diagnosis and prognosis. 
 
CD133 (Prominin-1) was identified as a marker expressed on hematopoietic 
stem cells, acute myeloid leukemia cells, neural stem cells and CSCs in brain 
tumors [22], [23] and [24]. In human melanoma biopsies, CD133 is expressed in 
17% of nevi, 39% of primary melanomas and 46% of metastatic melanoma [25]. 
As reported by Monzani et al., CD133 expressing cells comprised less than 1 % of 
total melanoma cells in 7 different human metastatic melanoma, but when 
xenotransplanted into NOD/SCID mice, CD133-positive cells generated tumors 
[26] (Table 1). Furthermore, CD133-expressing cells isolated from xenografts 
reverted to nearly 100% positivity upon culturing. These experiments suggest 
that CSCs might either display plasticity, having the ability to switch the surface 
phenotype depending on the environment, or that changing microenvironments 
act selectively on CD133-positive cells.  
 
The low-affinity neurotrophin receptor p75 (p75NTR, CD271) is often used as a 
marker for the prospective isolation of NCSCs from tissues and for ES-based 
derivation of NCSCs [27], [28], [29] and [30]. Supporting the concept that 
melanoma stem cells might display NCSC features, CD271 has recently been 
identified as a surface marker for tumor-initiating cells in melanoma [31] and 
[16] (Table 1). As shown by Boiko and colleagues, CD271 (p75NTR)-expressing 
melanoma cells had a higher tumor-initiation capacity than CD271-negative cells 
and, moreover, gave rise to metastases upon transplantation, unlike CD271-
negative cells [31]. As many other stem cells, CSCs are defined by their capacity 
to self-renew. To identify bona fide CSCs, serial transplantation in 
immunodeficient mice has, therefore, to be performed for several passages in 
vivo. Otherwise, the ability to induce tumor formation could reflect the 
engraftment capacity of tumor cells rather than their self-renewal in vivo. To 
address this issue, our laboratory performed serial transplantation in vivo using 
fully immunocompromized mice and demonstrated that the CD271-positive cell 
fraction displayed the ability to self-renew and to repeatedly establish 
heterogeneous tumors even after six passages in vivo. In contrast, tumors 
generated from CD271-negative cells exhausted with time and could only be 
propagated in vivo for maximally four passages [16]. Furthermore, CD271-
expressing melanoma cells were multipotent, generating tumors consisting of 
cells with melanocytic, neuronal, glial, and smooth muscle features, thereby 
consistently phenocopying the parental tumor from which they have been 
isolated. Thus, CD271-positive melanoma cells have a potential reminiscent of 
NCSCs and, by definition, are melanoma stem cells. 
 
 
3. Failure to detect melanoma-initiating cells exhibiting specific surface 
marker expression: a matter of tumor cell preparation? 
 
In contrast to the above mentioned studies, Morrison and colleagues challenged 
the concept of CSCs in melanoma using a modified assay for melanoma initiation 
[32] and [33]. Among other surface markers, Quintana et al. tested the capacity 
of ABCB5 and CD271 to discriminate between tumorigenic and non-tumorigenic 
cells. Although long-term tumor propagation was not assessed in these reports, 
there was no correlation between expression of specific surface markers and 
tumor initiation in a xenotransplantation assay. Another study by Bosenberg and 
colleagues also proposed that p75NTR (CD271) could not be used as a surface 
marker for melanoma-initiating cells in three different mouse models [34].  
 
In an attempt to resolve the discrepancy between these papers and studies 
describing specific CSC populations in melanoma [34], [32], [31] and [20] we 
compared the methods of enzymatic digestion used for tumor cell preparation: 
while our study and those by Boiko et al. and Schatton et al. used collagenase or 
collagenase/dispase to dissociate the tumor tissue [31], [16] and [20], the 
Morrison group used a modification of this protocol and applied a trypsin 
digestion step, in addition to collagenase. Likewise, Bosenberg and colleagues 
applied the protocol of Quintana et al., including an additional, more extensive 
step of trypsin digestion [32] and [34]. Obviously, using proteases in tissue 
dissociation is a crucial step that can affect the yield of cells selected by surface 
markers. Indeed, as shown in Civenni et al. [16], the addition of trypsin during 
tumor cell preparation reduces the number of CD271-positive cells detectable by 
FACS. For example, in a particular patient sample, 14.6% of all cells were scored 
as CD271 positive when trypsin was omitted, while including trypsin lowered 
the yield of marker-positive cells to only 1.4% in the same sample. A similar 
difference in detectable expression was also observed for another previously 
described marker of melanoma-initiating cells - ABCB5 [16].  
 
Thus, trypsin and possibly other enzymes used for tumor cell dissociation leads 
to partial shedding of surface markers and, therefore, to the contamination of 
supposedly marker-negative fractions by cells that will re-express the shedded 
marker, e.g. after transplantation (Fig. 1). Therefore, the chosen tumor 
dissociation protocol might have compromised studies that failed to detect CSCs 
in melanoma based on selective expression of specific surface markers. In 
general it has to be considered that the destruction of a cell’s surface proteome 
by harsh digestion procedures likely influences its interaction with surrounding 
tissue and hence its capacity to initiate tumors upon transplantation in vivo. 
 
 
4. Critical points to be considered when transplanting human melanoma 
cells into mouse models 
 
Does Matrigel provide an appropriate niche for tumor initiation and growth? 
 
To assess whether a tumor cell has CSC potential, the cell’s ability to establish, 
maintain, and propagate heterogeneous tumors has to be determined in vivo. For 
human tumor cells, such assays involve xenotransplantaion into an appropriate 
mouse model, which by nature of the experiment poses several problems 
regarding tumor-stroma and tumor-immune system interactions. To promote 
tumor cell survival and local growth, many groups have transplanted tumor cells 
embedded in Matrigel, which represents a solubilized mixture of basal 
membrane components, enriched in laminin, collagen IV, heparan sulfate 
proteoglycans. Several types of Matrigel can be used for transplantation assays, 
and it is likely that the type of Matrigel influences the outcome of the engrafting. 
Matrigel Matrix for example contains soluble growth factors such as TGF, EGF, 
IGF, and FGF, in addition to the abovementioned components. It is increasingly 
recognized that extracellular matrix (ECM) components might influence cellular 
signaling and subsequently the process of differentiation of cells (reviewed in 
[35]). In a recent study published by the group of Visvader and colleagues, the 
application of Matrigel in an in vivo mammary repopulating assays resulted in 
the promotion of a cell population with limited self-renewal capacity, distinct 
from bona fide mammary stem cells [36]. These results indicate that the addition 
of Matrigel in transplantation assays should be carefully evaluated. Does 
Matrigel resemble the natural niche for CSCs? Does it act selectively on tumor 
cell sub-populations? Does it promote changes in tumor cells that influence 
tumor take? The answers to these questions might be difficult to obtain, but are 
obviously relevant for a better understanding of how and to what extent 
endogenous, unmanipulated CSCs are involved in tumorigenesis in the patient. 
 
Finding the right niche: Orthotopic vs heterotopic  transplantation 
 
Unavoidably, the isolation of cells from human tumors leads to the destruction of 
the endogenous microenvironment that might act as a niche to control growth 
and survival of cancer cells. Orthotopic transplantation (transplantation of a cell 
into its normal location in the body) provides the most accurate cellular 
environment by supplying a new niche for survival and proliferation. 
Intriguingly, for cancers proven to follow the CSCs paradigm, such as breast 
cancers, brain tumors, and leukemia [24], [37], [38], and [39], researchers have 
spent great efforts to establish orthotopic transplantation assays. In the case of 
breast cancer, an assay was established, in which human breast cancer cells were 
propagated in the mouse mammary fat pad [37]. Furthermore, in brain tumors 
such as glioblastoma and medulloblastoma the presence of CSCs was tested by 
means of injection into the brains of NOD/SCID mice [24] and [38]. Finally, in the 
field of leukemia, where leukemic cells were assessed for their hierarchical 
organization, scientists used bone marrow transplantations [39] and [40]. In 
contrast to these examples, most of the studies on CSCs in melanoma rely on 
subcutaneous injections [17],[34],[32] and [16]. Skin is composed of two 
different layers, the epidermis and dermis. The subcutaneous layer, i.e. the layer 
beneath the skin, mostly consists of fat. However, adipocytes hardly provide the 
natural environment for melanoma cells, which in human originate in the 
epidermal-dermal junction or dermis. Therefore, normal survival, proliferation, 
and differentiation cues might not be provided, and signals that in a patient 
might never reach tumor-initiating cells might aberrantly influence the behavior 
of transformed cells. Transplanting melanoma cells subcutaneously could 
therefore lead to artifacts due to the lack of the CSC-supporting niche. 
Intriguingly, while most studies including those by Quintana et al. relied on 
subcutaneous injections of melanoma cells, Boiko et al. performed cell 
transplantations into the intradermal environment or even used full thickness 
human skin grafts to demonstrate the presence of CD271-positive melanoma-
initiating cells [32] and [31] (Table 1). Given that initial steps of 
melanomagenesis occur within the skin and not subcutaneously, these different 
experimental procedures should be taken into consideration when comparing 
and interpreting reports on melanoma initiation. 
 
Modulating metastasis formation in experimental models of melanoma 
 
Similarly, the method and site of injection conceivably influences the capacity of 
transplanted melanoma cells to engage in metastasis. Melanoma treatment 
becomes difficult and survival is significantly reduced when a patient has 
metastatic disease (stage III and stage IV). The danger of melanoma is that a 
relatively small primary tumor (stage III is characterized by the size of 
melanoma less than 1.0 mm and not more than 4 mm) is often already associated 
with the presence of metastases, indicating that the main threat of this cancer is 
its ability to spread to distant organs. One of the important points in modeling 
this disease is, therefore, to develop a system, which represents more advanced 
stages of melanoma pathogenesis. Unfortunately, with the exception of the study 
by Boiko et al. [31], most of the papers on CSCs in melanoma failed to 
demonstrate the presence of melanoma metastases after transplantation of 
melanoma cells into immunocompromized mice. One of the main reasons for this 
might again be the injection site: While injection into a subcutaneous 
environment leads to growth of an encapsulated tumor mass, intradermal 
injections rather provide the environment where melanoma cells can invade 
blood vessels and form metastases in distant organs [31]. These issues are 
relevant for the field, as CSCs have been functionally associated with the capacity 
to adopt mesenchymal features, to migrate, and to form metastases [31]. Thus, 
model systems are required, in which the relation between ‘stemness’ and tissue 
invasiveness of human melanoma can be assessed in a humanized environment 
mimicking the natural site of tumor formation [31] and  [41].  
 
 
 
 
The influence of the immune system on CSCs and tumor take 
 
Although orthotopic tumor cell injections and/or the use of a humanized 
environment for tumor cell transplantation allow proper tumor cell-stroma 
interactions, one component normally present in the patient has not been 
properly recapitulated in any xenotransplantation assay so far: The immune 
system, which appears to have a key influence on tumor initiation and growth 
[42]. While initial studies on CSCs in melanoma used partially 
immunocompromized mice [17] and  [20], Quintana et al. demonstrated a broad 
potential for tumor initiation using a fully immunodeficient NOD/SCID/Il2-/- 
(NSG) mice lacking T cells, B cells, and NK cells [32] (Fig. 2). Weisman and 
colleagues also used a mouse model (Rag2-/- c-/- mice) lacking T cells, B cells, 
and NK cells to identify CD271 as a marker for melanoma-initiating cells [31]. In 
Civenni et al [16], we compared tumor initiation and maintenance in partially 
immunocompromized NOD/SCID and Nude mice vs. fully immunocompromized 
NSG mice. Intriguingly, while CD271-negative human melanoma cells failed to 
initiate tumors in NOD/SCID and Nude mice, unlike CD271-positive cells, both 
cell fractions were able to initiate tumors in NSG mice. However, even in the fully 
immunocompromized NSG mouse model, presence of CD271-positive cells was 
required for long-term tumor propagation, as shown by serial transplantation. 
These data indicate two important issues to be considered: a) Tumor initiation 
might depend on distinct mechanisms or involve distinct cell populations than 
long-term tumor maintenance and propagation. By consequence, a tumor-
initiating cell is not necessarily equivalent to an actual CSC. In fact, it is likely that 
more cells in a tumor have the capacity to initiate tumor growth than there are 
cells able to sustain long-term tumor propagation and spreading. b) CSCs might 
possess specific capacities for immune system evasion or modulation. Indeed, 
when NK cells were depleted in NOD/SCID mice, this model system behaved like 
NSG mice and allowed tumor initiation also by CD271-negative melanoma cells 
[16]. Along these lines, ABCB5-expressing melanoma cells have recently been 
shown to suppress T cell activation, pointing to a specific capacity for immune 
system evasion by CSCs [43].  
 
Of course, immunogenic responses associated with xenotransplantation are 
presumably different from anti-tumorigenic immune responses observed in a 
patient fighting a tumor. But the data reveal the importance of immune system 
components that cannot be neglected when studying the relevance of CSCs for 
tumor formation. To provide a humanized immune system in mouse models, 
NSG mice have been engrafted with human CD34-positive hematopoietic 
progenitor cells, a system which leads to a partial reconstitution of human 
immune system components in immunodeficient mice [44] and [45]. Such 
models might offer a more physiological environment for human melanoma cells 
than mice lacking an immune system. However, to successfully implement this 
protocol, it would be necessary to obtain hematopoietic progenitors and tumor 
cells from the same patient. Ultimately, how the immune system interacts with 
CSCs and influences processes of melanoma formation can only be addressed in 
an appropriate genetic mouse model. 
 
 
 
5. Fate versus potential 
 
It is important to note that transplantation experiments always address the 
potential of cancer cells rather than their role and fate under the physiological 
conditions that the cells encounter in the patient. But how important is it for us 
to know the tumorigenic potential of a single human cancer cell in a mouse 
body? How to estimate the relevance of a cancer cell’s observed potential for 
future therapies? These are non-trivial questions, because a cell’s intrinsic 
capacity to differentiate and proliferate might be influenced by the experimental 
approach to an extent never occurring in the patient. A cancer cell might be 
subject to reprogramming events by its exposure to Matrigel, in vitro culture 
conditions, or an ectopic environment. For instance, while we observed dynamic 
CD271 expression in human melanoma cells under certain conditions in cell 
culture, absence of CD271-expression was a surprisingly stable trait in tumors 
obtained by subcutaneous injection of CD271-negative cells into NSG mice  
(Kiowski and Sommer, unpublished; [16]). In colon cancer, differentiated tumor 
cells can acquire stem cell features by the exposure to the hepatocyte growth 
factor (HGF) released from myofibroblasts [46]. Likewise, hypoxia in 
glioblastoma promotes a switch towards a stem cell-like phenotype in the non-
stem cell population, as shown by increased self-renewal and regulation of the 
CD133 stem cell marker [47], [48] and [49].  
 
Although the above-mentioned experiments unambiguously demonstrate the 
plasticity and dynamic behavior of cancer cells in vitro, it is unclear whether 
similar processes of de- and re-differentiation occur in vivo. Dynamic changes in 
surface proteome expression and intrinsic properties could occur in vivo, for 
instance, as a consequence of an epithelial-to-mesenchymal transition (EMT) 
[50] or in response to the changing environment encountered by an invasive cell. 
Such changes likely involve epigenetic regulation on the level of e.g. DNA 
methylation or histone modifications. Intriguingly, expression of the chromatin-
modifying enzyme Jarid1B is dynamically regulated on melanoma cells [51]. 
Presence of Jarid1B appears to correlate with the potential of a melanoma cell to 
act as a CSC, although it is unclear whether this is associated with a specific cell 
surface marker profile. In accordance with this, Jarid1B knock-down, and thus 
interference with a specific ‘epigenetic status’, counteracted the cells’ capacity to 
maintain continuous tumor growth. Thus, a CSC potential might well be 
dynamically regulated. The question that interests the most, however, is under 
which circumstances this potential is realized in the patient. 
 
In this context, the importance of recently described in vivo lineage tracing 
experiments in mouse models of skin, intestinal and brain cancers cannot be 
underestimated [1], [3] and [2]. In these elegant studies, researchers traced 
single tumor cells in their naïve environment and provided for the first time 
solid evidence that selected cells within a growing tumor act as CSCs that 
establish and maintain tumor cell hierarchies. Although CSCs remain to be 
discovered in vivo in melanoma and other cancers, these findings indicate that 
specific subpopulations of tumorigenic cells might indeed represent suitable 
targets for therapy. Moreover, the studies emphasize the significance of 
assessing CSCs and their properties in in vivo mouse models in an undisturbed 
environment. 
 
 
6. Targeting cancer stem cells in the clinics  
 
The CSC hypothesis predicts that efficient therapies should eliminate CSCs, in 
addition to destroying the bulk tumor. Based on our knowledge on CSCs, two 
potential strategies emerge to target these cells in the clinics: The aim of the first 
approach is to suppress ‘stemness’ by targeting specific signaling pathways or 
regulatory transcriptional networks utilized by CSCs for their self-renewal and 
survival. A second approach consists in eliminating CSCs based on the expression 
of unique surface antigens. For instance, the frequency of CD271-positive cells in 
human melanoma samples correlates with higher metastatic potential and worse 
prognosis, suggesting that this cell type represents a possible target for therapy 
[16]. For both strategies, however, there is a risk of side effects due to potential 
lack of specificity. Compounds targeting CSCs should optimally be tested in 
genetic mouse models, in which primary tumors and metastases arise de novo 
rather than upon transplantation. Such models allow the assessment of drug 
efficacies without manipulating (and hence potentially changing) tumor cell 
properties. Moreover, in such mice, target specificity can be preclinically tested, 
taking into consideration undesired effects on other cell populations including 
normal stem cells. 
 
A successful example of the first approach, namely targeting signaling pathways 
regulating “stemness” of CSCs, is our recent study revealing that reducing 
expression levels of the NCSC transcription factor Sox10 completely abolishes 
melanoma formation both in a genetic mouse model (Tyr::NrasQ61K INK4a-/- mice; 
[52]) and upon xenotransplantation of human melanoma cells [10] (Fig. 3). 
Sox10 was previously shown to play a crucial role in the maintenance of stem 
cell characteristics in NCSCs. Interfering with Sox10 activity in NCSCs results in 
the acquisition of mesectodermal features, reduced proliferation, and increased 
apoptosis [53], [54] and [55]. Similarly, reduced Sox10 levels in Tyr::NrasQ61K 
INK4a-/- mice heterozygous for a Sox10 mutation counteracted oncogene-
induced proliferation of melanoma cells. In cell culture, knockdown of SOX10 in 
human melanoma cell lines suppressed neural crest cell “stemness” and led to 
similar effects as previously observed upon Sox10 loss-of-function in NCSCs, 
such as a “switch” of identity from a melanocytic to a mesodectodermal program, 
decreased cell cycle progression, and reduced survival. In addition, the 
percentage of cells expressing CD271 was strongly reduced upon SOX10 
knockdown in vitro, suggesting that SOX10 controls CSC numbers in melanoma 
[10]. Taken together, these data strongly indicate that blocking stem cell 
properties in melanoma exerts a drastic effect on tumor initiation and growth, 
leading to complete tumor ablation. In conclusion, drugs potentially interfering 
with signaling pathways or molecules controlling “stemness” of NCSCs might 
prevent tumor formation and expansion. 
 
Most recently, several groups provided evidence that the alternative 
therapeutical approach mentioned above, namely to target CSCs based on 
specific expression of surface markers, might actually be beneficial for melanoma 
patients [56] and [57]. Abken and colleagues achieved a targeted disruption of a 
CD20-positive cell population via engineering T cells with a chimeric antigen 
receptor (CAR), thereby redirecting specificity of cytotoxic T cells towards CD20-
expressing cells [56]. Of note, the CD20-positive cell population represented less 
than 2% of all melanoma cells. When melanoma cells from five different human 
biopsies were xenotransplanted into immunodeficient mice lacking T, B, and NK 
cells, tumors were eradicated by application of engineered T cells. Extending 
CD20 experiments into the clinics, a study published by Wagner and colleagues 
presented the results of a pilot experiment, where they have applied rituximab 
(anti-CD20 antibody) treatment in a group of nine patients with metastatic 
melanoma at clinical stage IV [57]. After a treatment period of 2 years, and a 
subsequent median follow-up time of 42 months, two thirds of the patients 
included in this study were recurrence-free, without any signs of major side 
effects or toxicity [57]. CD20 is also expressed on the surface of B cells, and 
rituximab therapy is used to treat B-cell lymphoma [58]. Therefore, it is not 
surprising that anti-CD20 treatment of melanoma patients resulted not only in 
depletion of CD20-positive melanoma cells, but also in consistent loss of B 
lymphocytes in the peripheral blood. B cells are commonly activated in cancer 
patients and melanoma samples often contain CD20-positive lymphocytes [59] 
and [60], although the role of these cells in tumors still remains to be clarified. 
While in some cancers, depletion of B cells by using CD20 antibodies enhances 
tumor growth, as is the case for B16 melanoma [61], CD20 therapy may also 
result in the protection against tumor [62]. Furthermore, retuximab is known for 
its antiproliferative effect, at least partially via induction of cell cycle kinase 
inhibitors [63], [64] and [65]. Whatever the mechanism of rituximab’s action is 
in melanoma, the first reports using an anti-CD20 therapy are promising. 
Moreover, these studies suggest that elimination of a restricted melanoma cell 
fraction, characterized by specific cell surface marker expression, might 
represent a valid therapeutical strategy. Ultimately, there will be no single 
therapy for the elimination of melanoma cells, and a successful therapy will most 
likely require the combination of several drugs in order to efficiently eradicate 
all cancer cells.  
 
 
7. Final conclusions and remarks 
 
Given the discrepancies and open questions existing in the field, it is valid to 
further test and challenge the CSC hypothesis in melanoma. Most importantly, it 
will be critical to assess the relevance of the CSC concept in melanoma using 
appropriate model systems. Given the importance of the immune system in 
tumorigenesis, it can be questioned whether immunocompromized mice are 
suitable models to study mechanisms of human cancer progression. In any case, 
the method of tumor cell preparation and the site of tumor cell transplantation 
has to be carefully chosen, and potentially artificial changes caused by tumor cell 
manipulation have to be taken into account. It becomes more and more apparent 
that the most determining proof of the CSC hypothesis is a successful targeted 
therapy directed against surface epitopes expressed on CSCs or against specific 
stem cell properties exhibited by a selected melanoma cell fraction. Hence, the 
CSC theory is awaiting its final and most relevant test in the clinics. 
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Figure Legends 
 
Fig. 1. Choosing the appropriate method for tumor cell preparation to test the 
CSC theory. When melanoma tissue is dissociated by enzymatic digestion with 
collagenase or a combination of dispase and collagenase, the expression of 
markers on the surface of a cell is better preserved than upon treatment of 
melanoma cells with trypsin. Using trypsin and other harsh dissociation 
procedures can result in reduced numbers of marker-positive cells detectable by 
FACS. This can subsequently lead to the presence of false-negative cells within 
the “negative fraction”. These cells can re-express surface markers and initiate 
tumorigenesis upon transplantation.  
 
 
Fig. 2. Melanoma initiation and the immune system. The capacity of CD271-
expressing cells to give rise to melanoma upon xenotransplantation depends on 
the immune system status of the recipient mouse. After tissue dissociation and 
FACS isolation, melanoma cells are injected into immunodeficient mice. When 
CD271-negative cells are transplanted into partially immunocompromized mice 
(Nude mice lack T cells, while NOD/SCID mice lack T and B cells), there is no 
melanoma formation. In contrast, fully immunocompromized NSG mice lacking 
T, B, and NK cells, provide a permissive environment for CD271-negative cells. 
Tumors generated by CD271-negative cells, however, appear to have a different 
cellular composition than tumors derived from CD271-positive cells and cannot 
be propagated extensively.  
 
Fig. 3. Interfering with NCSC properties abolishes tumor formation in a genetic 
mouse model of melanoma and in human melanoma cells. a) Mice carrying 
mutations also found in human patients develop congenital nevi and subsequent 
melanoma. Oncogenic NRasQ61K in this model leads to upregulation of the NCSC 
transcription factor Sox10. Deletion of one Sox10 allele is sufficient to counteract 
NRasQ61K-dependent nevus formation and tumorigenesis. b) SOX10 expression in 
human melanoma cells promotes self-renewal and allows acquisition of 
melanocytic traits. As in normal NCSCs, suppression of SOX10 activity leads to 
decreased self-renewal, increased cell death, preferential acquisition of a non-
melanocytic fate and loss of p75/CD271, a marker for tumor-initiating cells. 
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